Depo-Testosterone: Immunomodulating Allergic Rhinitis in Hypogonadal U.S. Males
Reading Time: 2 minutes Introduction Allergic rhinitis, commonly known as hay fever, affects over 60 million Americans annually, with a notable prevalence among males aged 20-64, where environmental allergens exacerbate symptoms like nasal congestion, sneezing, and pruritus. In the United States, hypogonadism—characterized by deficient testosterone production—affects approximately 4-5 million men, correlating with dysregulated immune responses. Pfizer's Depo-Testosterone (testosterone cypionate injectable suspension) has emerged as a cornerstone of testosterone replacement therapy (TRT), traditionally prescribed for hypogonadism. Emerging immunological research suggests testosterone's pleiotropic effects may modulate Th2-dominant allergic pathways, potentially offering adjunctive benefits for allergy management in American males. This article elucidates the mechanistic underpinnings, clinical...




